Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
